Literature DB >> 9539189

Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty.

F H Luyckx1, C Desaive, A Thiry, W Dewé, A J Scheen, J E Gielen, P J Lefèbvre.   

Abstract

OBJECTIVE: To examine the factors associated with liver steatosis in severely obese subjects and to test the potential reversibility of fatty liver after weight loss.
DESIGN: Retrospective clinical study. SUBJECT: 528 obese patients before bariatric surgery and 69 obese subjects of the initial cohort evaluated before and 27+/-15 months after gastroplasty. MEASUREMENTS: Fatty deposition (scored as mild, moderate or severe) and inflammatory changes were evaluated in liver biopsies; clinical (body mass index (BMI), age, gender, duration of obesity) and biological (glucose, triglycerides, liver enzymes) parameters were related to histological findings.
RESULTS: 74% of the 528 biopsies showed fatty change, estimated as mild in 41% of cases, moderate in 32% and severe in 27%. The prevalence of steatosis was significantly higher in men than in women (91% vs 70%, P = 0.001) and in patients with impaired glucose tolerance or type 2 diabetes compared with nondiabetics (89% vs 69% P = 0.001). The severity of the steatosis was associated with BMI (P = 0.002) but not with the duration of obesity or the age of the patient. When compared with patients without fatty change, those with liver steatosis had significantly higher fasting plasma glucose (5.5 mmol/l vs 5.1 mmol/l, P = 0.007) and triglycerides (1.8 mmol/l vs 1.3 mmol/l, P = 0.002). Mean serum liver enzyme activities (alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl-transpeptidase (gammaGT) were significantly (P < 0.001) increased in patients with fatty change but remained within laboratory reference values. In the 69 patients who have been evaluated after a marked weight reduction (-32+/-19kg), 45% of the biopsies were considered as normal (vs 13% before, P < 0.001) while pure fatty change was still observed in 38% of the patients (vs 83% before, P = 0.001). However, the severity of the steatosis was significantly (P < 0.001) reduced (mild: 62% vs 21%; moderate: 23% vs 37%; severe: 15% vs 42%). In addition, a significant increase of hepatitis was observed in 26% of the biopsies (vs 14% before, P < 0.05).
CONCLUSIONS: Liver steatosis in obese subjects is associated with men, diabetic status, BMI, higher fasting glucose and hypertriglyceridaemia. Postgastroplasty weight loss reduces liver steatosis, but seems to increase the incidence of inflammatory lobular hepatitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9539189     DOI: 10.1038/sj.ijo.0800571

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  103 in total

1.  The utility of Xenon-133 liver scan in the diagnosis and management of nonalcoholic fatty liver disease.

Authors:  Said A Al-Busafi; Peter Ghali; Philip Wong; Javier A Novales-Diaz; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

2.  Outcomes of Bariatric Surgery in Patients with Cirrhosis.

Authors:  Inka Miñambres; Miguel Angel Rubio; Ana de Hollanda; Irene Breton; Nuria Vilarrasa; Silvia Pellitero; Marta Bueno; Albert Lecube; Clara Marcuello; Albert Goday; Maria D Ballesteros; German Soriano; Assumpta Caixàs
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

3.  Lifestyle Modification through Dietary Intervention: Health Promotion of Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Seyed Rafie Arefhosseini; Mehrangiz Ebrahimi-Mameghani; Alireza Farsad Naeimi; Manoochehr Khoshbaten; Javad Rashid
Journal:  Health Promot Perspect       Date:  2011-12-20

4.  Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery.

Authors:  Yosuke Seki; Satoru Kakizaki; Norio Horiguchi; Hiroaki Hashizume; Hiroki Tojima; Yuichi Yamazaki; Ken Sato; Motoyasu Kusano; Masanobu Yamada; Kazunori Kasama
Journal:  J Gastroenterol       Date:  2015-08-28       Impact factor: 7.527

5.  Hepatic decompensation after gastric bypass surgery for severe obesity.

Authors:  Scott J Cotler; Joseph M Vitello; Grace Guzman; Giuliano Testa; Enrico Benedetti; Thomas J Layden
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

Review 6.  Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.

Authors:  Norberto-C Chavez-Tapia; Tonatiuh Barrientos-Gutierrez; Felix-I Tellez-Avila; Francisco Sanchez-Avila; Maria-Antonieta Montano-Reyes; Misael Uribe
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 7.  Benefits of lifestyle modification in NAFLD.

Authors:  Stephen A Harrison; Christopher Paul Day
Journal:  Gut       Date:  2007-10-02       Impact factor: 23.059

Review 8.  Nonalcoholic fatty liver disease: a clinical review.

Authors:  David A Sass; Parke Chang; Kapil B Chopra
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

Review 9.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology.

Authors:  Guy Bower; Tania Toma; Leanne Harling; Long R Jiao; Evangelos Efthimiou; Ara Darzi; Thanos Athanasiou; Hutan Ashrafian
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

Review 10.  The metabolic syndrome and nonalcoholic fatty liver disease in children.

Authors:  Shikha S Sundaram; Phil Zeitler; Kristen Nadeau
Journal:  Curr Opin Pediatr       Date:  2009-08       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.